Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.50 USD
Change Today -0.04 / -0.72%
Volume 451.7K
PGNX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$5.56
Previous Close
$5.54
Day High
$5.63
Day Low
$5.42
52 Week High
01/2/15 - $7.84
52 Week Low
06/4/14 - $3.31
Market Cap
383.0M
Average Volume 10 Days
703.0K
EPS TTM
$0.04
Shares Outstanding
69.6M
EX-Date
--
P/E TM
127.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

57 Employees
Last Reported Date: 03/16/15
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $555.7K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $289.0K
Executive Vice President of Innovation
Total Annual Compensation: $440.9K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Compensation as of Fiscal Year 2014.

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Progenics Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $248,000 against $1,815,000 for the same period a year ago, reflecting RELISTOR royalty income of $0.1 million compared to $0.7 million in the 2014 period, based on net sales reported to the company by its commercialization partner, Valeant Pharmaceuticals International, Inc. The decrease in royalty revenue reflects a short-term wholesaler inventory reduction initiative implemented in the fourth quarter of 2014 by Salix Pharmaceuticals, Inc., which was subsequently acquired by Valeant. In addition, collaboration revenue declined to $0.1 million from $1.0 million in the 2014 period, primarily due to a milestone from Fuji recognized in the first quarter of 2014. Operating loss was $10,266,000 against $9,325,000 for the same period a year ago. Net loss was $10,254,000 or $0.15 per basic and diluted share against $9,313,000 or $0.15 per basic and diluted share for the same period a year ago.

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. Announces RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

April 24, 2015 Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic non-cancer pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $5.50 USD -0.04

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.71 USD -0.03
Genocea Biosciences Inc $10.92 USD -0.05
Peregrine Pharmaceuticals Inc $1.32 USD -0.01
Rigel Pharmaceuticals Inc $3.56 USD -0.12
Transgene SA €4.97 EUR 0.00
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 100.0x
Price/Sales 8.9x
Price/Book 3.3x
Price/Cash Flow 95.7x
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.